Literature DB >> 7534635

Hodgkin's and non-Hodgkin's lymphomas.

P Hartge1, S S Devesa, J F Fraumeni.   

Abstract

Incidence of HD varies from about 0.5 per 100,000 person-years in parts of Asia to over 3 in parts of North America. In recent decades, many registries have reported slightly declining age adjusted incidence among men and women. Some lymphomas previously diagnosed as HD now would be classified as NHL, but this shift does not explain all of the decline. When analysed by age group, incidence has decreased substantially at older ages, whereas increases have been reported among young adults in some industrial countries. Less developed countries continue to show high rates in childhood. Hodgkin's disease of the nodular sclerosis subtype has increased over time, whereas HD of mixed cellularity has declined. Improved therapy for HD has led to sharply declining mortality rates, but further understanding of the role of EBV and other possible causal agents should afford opportunities for prevention. Non-Hodgkin's lymphoma stands out from most other malignancies because incidence and mortality rates have risen dramatically, steadily and almost universally during the past few decades. Incidence overall has been rising 3-4% per year. No sudden rise has occurred in specific birth cohorts or calendar year of diagnosis, although incidence rates have increased more steeply at older ages. Diagnosis of NHL has improved with time, perhaps beyond the ways considered herein, but has it improved so much more than diagnosis of other malignancies, and roughly simultaneously around the world? Although it appears that diagnostic improvements are partly responsible for the upward trend, it is likely that aetiological factors are playing an important part. Infections with HIV have started to inflate NHL incidence rates further but cannot account for the striking trend already under way for several decades. Clues should be vigorously pursued to determine the role of other known viruses, immunosuppressive states, herbicides and other chemicals in the environment, and commercial products such as hair dyes. To clarify reasons for the upward trends and to take preventive action will require a better understanding of the origins of the lymphomas through epidemiological research, including interdisciplinary approaches that can identify new viruses, host-environmental interactions and lifestyle and other exposures that alter susceptibility.

Entities:  

Mesh:

Year:  1994        PMID: 7534635

Source DB:  PubMed          Journal:  Cancer Surv        ISSN: 0261-2429


  19 in total

1.  Sunlight exposure and non-Hodgkin's lymphoma.

Authors:  E Weir
Journal:  CMAJ       Date:  2001-08-07       Impact factor: 8.262

2.  Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001.

Authors:  Lindsay M Morton; Sophia S Wang; Susan S Devesa; Patricia Hartge; Dennis D Weisenburger; Martha S Linet
Journal:  Blood       Date:  2005-09-08       Impact factor: 22.113

3.  Genotype frequency and F ST analysis of polymorphisms in immunoregulatory genes in Chinese and Caucasian populations.

Authors:  Qing Lan; Min Shen; Dino Garcia-Rossi; Stephen Chanock; Tongzhang Zheng; Sonja I Berndt; Vinita Puri; Guilan Li; Xingzhou He; Robert Welch; Shelia H Zahm; Luoping Zhang; Yawei Zhang; Martyn Smith; Sophia S Wang; Brian C-H Chiu; Martha Linet; Richard Hayes; Nathaniel Rothman; Meredith Yeager
Journal:  Immunogenetics       Date:  2007-10-16       Impact factor: 2.846

4.  Non-Hodgkin's lymphoma and skin cancer. Ultraviolet light is unlikely explanation for association.

Authors:  P Sasieni; V Bataille
Journal:  BMJ       Date:  1995-09-16

5.  Genetic variation in Th1/Th2 pathway genes and risk of non-Hodgkin lymphoma: a pooled analysis of three population-based case-control studies.

Authors:  Qing Lan; Sophia S Wang; Idan Menashe; Bruce Armstrong; Yawei Zhang; Patricia Hartge; Mark P Purdue; Theodore R Holford; Lindsay M Morton; Anne Kricker; James R Cerhan; Andrew Grulich; Wendy Cozen; Shelia H Zahm; Meredith Yeager; Claire M Vajdic; Maryjean Schenk; Brian Leaderer; Jeff Yuenger; Richard K Severson; Nilanjan Chatterjee; Stephen J Chanock; Tongzhang Zheng; Nathaniel Rothman
Journal:  Br J Haematol       Date:  2011-03-21       Impact factor: 6.998

6.  High-dose methotrexate, high-dose cytarabine and temozolomide for the treatment of primary central nervous system lymphoma (PCNSL).

Authors:  Maher Salamoon; Taisir Hussein; Mazen Kenj; Marrouan Bachour
Journal:  Med Oncol       Date:  2013-08-20       Impact factor: 3.064

Review 7.  Relationship between Hodgkin's and non-Hodgkin's lymphomas.

Authors:  Rose-Marie Amini; Gunilla Enblad
Journal:  Med Oncol       Date:  2003       Impact factor: 3.064

8.  Lymphomas in Ile-Ife, Nigeria: Immunohistochemical Characterization and Detection of Epstein-Barr virus Encoded RNA.

Authors:  Ifeyinwa M Onwubuya; Kayode A Adelusola; Muheez A Durosinmi; Donatus Sabageh; Kevin N Ezike
Journal:  J Clin Diagn Res       Date:  2015-06-01

9.  Exploring risk factors for follicular lymphoma.

Authors:  Alexander J Ambinder; Pareen J Shenoy; Neha Malik; Alison Maggioncalda; Loretta J Nastoupil; Christopher R Flowers
Journal:  Adv Hematol       Date:  2012-09-18

10.  Epidemiologic overview of malignant lymphoma.

Authors:  Jooryung Huh
Journal:  Korean J Hematol       Date:  2012-06-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.